Clinical Trials Logo

B-cell Malignancy clinical trials

View clinical trials related to B-cell Malignancy.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05643742 Recruiting - Clinical trials for Mantle Cell Lymphoma

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Start date: March 10, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX112™ in subjects with relapsed or refractory B-cell malignancies.

NCT ID: NCT05602363 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Start date: August 1, 2023
Phase: Phase 1
Study type: Interventional

This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.

NCT ID: NCT05294731 Recruiting - Clinical trials for Mantle Cell Lymphoma

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

Start date: March 24, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study aims to explore the recommended phase 2 dose and evaluate the safety, tolerability and preliminary antitumor activity of BGB-16673 monotherapy at the recommended Phase 2 dose for the selected B-cell malignancy expansion cohorts

NCT ID: NCT05106946 Recruiting - B-cell Malignancy Clinical Trials

Safety and Clinical Activity of ThisCART22 in Patients With r/r Non-Hodgkin's B Cell Lymphoma

Start date: October 25, 2021
Phase: Phase 1
Study type: Interventional

A single arm, open-label, dose-escalation study to evaluate the safety and clinical activity of ThisCART22 (Allogeneic CAR-T targeting CD22) in patients with relapsed and/or refractory non-Hodgkin's B cell lymphoma (r/r B-NHL).

NCT ID: NCT05106907 Recruiting - B-cell Malignancy Clinical Trials

Safety and Clinical Activity of ThisCART19 in Patients With r/r Non-Hodgkin's B Cell Lymphoma

Start date: October 25, 2021
Phase: Phase 1
Study type: Interventional

A single arm, open-label, dose-escalation study to evaluate the safety and clinical activity of ThisCART19 (Allogeneic CAR-T targeting CD19) in patients with relapsed and/or refractory non-Hodgkin's B cell lymphoma (r/r B-NHL).

NCT ID: NCT05006716 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Start date: September 13, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)

NCT ID: NCT04601181 Recruiting - B Cell Malignancy Clinical Trials

Safety and Efficacy of ThisCART22 in Patients With Refractory or Relapsed B Cell Malignancies

Start date: October 23, 2020
Phase: Phase 1
Study type: Interventional

This is a single-center, nonrandomized, open-label, study to evaluate the safety and clinical activity of allogeneic CAR-T targeting CD22 in patients with refractory or relapsed CD22-positive B cell malignancies

NCT ID: NCT04384393 Recruiting - B Cell Malignancy Clinical Trials

Safety and Efficacy of ThisCART19 in Patients With Refractory or Relapsed B Cell Malignancies

Start date: May 9, 2020
Phase: Phase 1
Study type: Interventional

This is a study to evaluate the safety and clinical activity of ThisCART19 (Allogeneic CAR-T targeting CD19) in patients with refractory or relapsed CD19 positive B cell malignancies.

NCT ID: NCT03559439 Recruiting - B-cell Lymphoma Clinical Trials

CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies

Start date: April 24, 2018
Phase: Phase 1
Study type: Interventional

This is a single center, single arm, open-label phase 1 study to determine the safety and efficacy of autologous T cells expressing CD19 chimeric antigen receptors in adults with CD19+ B cell malignancies.